Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Agreement extension

19 Oct 2005 07:00

Marchpole Holdings PLC19 October 2005 For Immediate Release 19 October 2005 Marchpole Holdings plc Marchpole expands Jean-Charles de Castelbajac ("JCC") in Japan Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands, is pleased to announce that afurther agreement has been reached with their Japanese partner, Itochu, inrelation to a new Jean-Charles de Castelbajac clothing line and flagship storeopenings. The agreement with Itochu, which will commence for Autumn Winter 2006, will seethe launch of a new clothing line unique to the Japanese market. Under the termsof the new agreement, Itochu will pay JCC a design fee of 3% based on sales madein the territory with an annual minimum royalty which has been agreed over theinitial three year term as Euro 420,000 (£290,000). Itochu have also given further support to the roll out of JCC in Japan with acommitment to open two flagships stores, one in Kobe and the other in Tokyo. Thedesign of the stores will be based on the concept store in Paris with a launchdate of Autumn Winter 2006. Itochu already achieves retail sales of Euro 80 million (£55 million) on theexisting Castelbajac license agreement, and the design fee on these sales hasbeen increased to 2.5% of wholesale value (Euro 25 millions) as of 1 October2005. For further information, please contact: Marchpole Holdings plc020 7908 7700Greg Tufnell, Chief ExecutiveMichael Morris, Executive Director Buchanan Communications020 7466 5000Tim ThompsonNicola Cronk Notes to editors Marchpole is brand manager for six high quality labels: Emanuel Ungaro; Ungaro;Yves Saint Laurent; Boateng; Jean-Charles de Castelbajac ('JCC') andJean-Charles de Castelbajac / Rossignol. In June this year, Marchpole announced its results for the year ended 31 March2005, with turnover up 62% at £32.5 million and profit before tax up 79% at £4.7million. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.